KT

Kalaris Therapeutics Inc

KLRS·NASDAQ

$4.66

-1.3%
HealthcareBiotechnology

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

At a Glance

Live Snapshot
Market Cap$87.15M
EPS-2.8500
P/E Ratio-1.64
Earnings Date08/12/2026

klrs

Net Debt Issuance

Last Annual Value

7.50M

3-Year CAGR

20%

5-Year CAGR

%

10-Year CAGR

%

KT

Kalaris Therapeutics Inc Competitors Analysis of Net Debt Issuance

KLRS · NASDAQ
CompanyNet Debt Issuance
CAGR 3Y
CAGR 5Y
CAGR 10Y
7.50M
7.7%N/AN/A 
0.00
N/AN/AN/A
-132.00K
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
-1.36M
N/AN/AN/A
-457.00K
N/AN/AN/A
-2.06M
N/AN/AN/A
0.00
N/AN/AN/A
KT

Kalaris Therapeutics Inc Fair Value Envelope

KLRS · NASDAQ

Our analysis suggests that KLRS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.66, this represents a potential HIDDEN relative to our calculated worth for Kalaris Therapeutics Inc.

Intrinsic Value
Current Price: $4.66